Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04031885 · ClinicalTrials.gov registry record · Phase 4
A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
A Phase 4 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT04031885 is a Phase 4 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 4 participants.
The verdict
NCT04031885, a Phase 4 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
The reason for this study is to compare the efficacy of abemaciclib, in combination with fulvestrant, to that of physician's choice of chemotherapy in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer that has spread to internal organs. Your participation in this trial could last up to 31 months, depending on your cancer type and how you and your tumor respond.
Interventions
- DRUG Fulvestrant
- DRUG Abemaciclib
- DRUG Standard Chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-08-14 |
| Est. Completion | 2020-08-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04031885
The ClinicalTrials.gov registry entry for NCT04031885 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fulvestrant is the first listed.
NCT04031885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04031885 about?
NCT04031885 is a clinical study titled "A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer". The reason for this study is to compare the efficacy of abemaciclib, in combination with fulvestrant, to that of physician's choice of chemotherapy in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer that has spread to int...
What is the current status of trial NCT04031885?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2019-08-14. Estimated completion is 2020-08-11.
What interventions are being tested in trial NCT04031885?
The interventions under investigation include: Fulvestrant (DRUG), Abemaciclib (DRUG), Standard Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT04031885?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.